5/18
Positive
Late treatment study
et al., medRxiv, doi:10.1101/2020.05.13.20094193 (Preprint)
Treatment Response to Hydroxych loroquine, Lopinavir/Ritonavir, and Antibiotics for Moderate COVID 19: A First Report on the Pharmacological Outcomes from South Korea
Retrospective of 97 moderate cases. Time to viral clearance significantly shorter for HC Q+antibiotic. Preprint withdrawn pending peer review.
hospitalization time, ↓51.0%, p=0.01
time to viral-, ↓56.0%, p=0.005
time to viral-, ↓56.0%, p=0.005